Second-line treatment of patients with advanced NSCLC, including LSQCC, with anti-PD1 agents pembrolizumab and nivolumab and anti-PD-L1 agent atezolizumab prolonged survival compared to standard chemotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.